Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Liabilities and Shareholders Equity (2020 - 2025)

IceCure Medical (ICCM) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $13.9 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 10.43% to $13.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $73.1 million through Dec 2025, down 20.11% year-over-year, with the annual reading at $13.9 million for FY2025, 10.43% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $13.9 million at IceCure Medical, up from $12.6 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $32.3 million in Q4 2021, with the low at $12.6 million in Q4 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $21.1 million, with a median of $16.4 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 215.27% in 2021, then tumbled 45.64% in 2023.
  • Over 5 years, Liabilities and Shareholders Equity stood at $32.3 million in 2021, then decreased by 6.48% to $30.2 million in 2022, then plummeted by 45.64% to $16.4 million in 2023, then dropped by 23.36% to $12.6 million in 2024, then grew by 10.43% to $13.9 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $13.9 million, $12.6 million, and $16.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.